Google
Trusted Resources: News & Events
Latest announcements and gatherings
Gamida Cell Announces $3.5 Million Grant from the Israeli Government
Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that it has been awarded a grant of $3.5 million from the Israel Innovation Authority (IIA) of the Israeli Ministry of Economy and Industry. The mission of the IIA is to encourage innovation and entrepreneurship in various industries, including science and technology, while stimulating economic growth.
The non-dilutive funding, combined with the $40 million financing round, will support Gamida Cell’s ongoing research and development efforts, including its Phase 3 registration study of NiCord for hematological malignancies, such as leukemia and lymphoma, its clinical trials of CordIn for sickle cell disease and thalassemia, and its NK cell therapy for blood and solid cancers.
+myBinderRelated Content
-
Crizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data showNovartis’ investigational th...
-
Screening for Obstructive Sleep Apnea in Children With Sickle Cell Disease: A Pilot StudyObjectives/Hypothesis: Obstructive slee...
-
Calimmune Expands Lentiviral Gene Therapy Pipeline Through License of Sickle Cell Disease Therapeutic CandidateLicense of Gamma-Globin from Cincinnati ...
-
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickl...Although allogeneic haematopoietic stem ...
-
Bioverativ and Sangamo announce FDA acceptance of IND application for gene-edited cell therapy BIVV003 to treat sick...Bioverativ Inc., a Sanofi company dedi...
-
Sickle Cell Patients are Innocent Victims of the Opioid Epidemic: Samir K. Ballas, MDhttps://www.youtube.com/watch?v=BOhY_gJo...
-
Blood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.